Key Points
- CEO Marshall Fordyce sold 18,500 Vera Therapeutics shares at an average price of $35.12, generating $649,720. The transaction, conducted under a Rule 10b5-1 plan, reduced his direct holdings by 7.29% to 235,244 shares.
- VERA shares opened at $35.89, with a market capitalization of approximately $2.59 billion and a one-year trading range of $21.96 to $56.05. The company recently reported a quarterly loss of $1.52 per share, slightly better than analysts’ expected loss of $1.58.
- Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus rating and an average price target of $81.15. Institutional investors own 99.21% of the company’s outstanding stock.
Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 18,500 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $35.12, for a total transaction of $649,720.00. Following the completion of the transaction, the chief executive officer directly owned 235,244 shares in the company, valued at $8,261,769.28. This trade represents a 7.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Marshall Fordyce also recently made the following trade(s):
- On Tuesday, July 7th, Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00.
- On Tuesday, June 23rd, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $37.93, for a total value of $701,705.00.
Vera Therapeutics Stock Performance
Shares of VERA stock opened at $35.89 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92. The stock has a market cap of $2.59 billion, a PE ratio of -6.12 and a beta of 0.96. The stock has a 50-day moving average of $35.86 and a 200-day moving average of $37.46. Vera Therapeutics, Inc. has a one year low of $21.96 and a one year high of $56.05.
Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, topping the consensus estimate of ($1.58) by $0.06. During the same quarter in the prior year, the business posted ($1.20) EPS. As a group, sell-side analysts expect that Vera Therapeutics, Inc. will post -6.45 earnings per share for the current year.
Institutional Investors Weigh In On Vera Therapeutics
Several institutional investors have recently bought and sold shares of the company. Los Angeles Capital Management LLC acquired a new stake in shares of Vera Therapeutics in the fourth quarter valued at approximately $46,000. Quantbot Technologies LP acquired a new position in Vera Therapeutics during the second quarter worth $51,000. Aster Capital Management DIFC Ltd bought a new position in Vera Therapeutics in the fourth quarter valued at $71,000. Nykredit A S bought a new position in Vera Therapeutics in the second quarter valued at $97,000. Finally, Tower Research Capital LLC TRC increased its stake in Vera Therapeutics by 192.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company's stock valued at $99,000 after buying an additional 2,757 shares during the last quarter. Institutional investors own 99.21% of the company's stock.
Analysts Set New Price Targets
Several analysts recently commented on VERA shares. The Goldman Sachs Group reaffirmed a "buy" rating and set a $90.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Bank of America increased their price target on Vera Therapeutics from $65.00 to $70.00 and gave the stock a "buy" rating in a report on Tuesday, July 7th. Wedbush reaffirmed a "neutral" rating and set a $34.00 price target on shares of Vera Therapeutics in a research report on Monday, August 17th. Guggenheim lifted their price objective on Vera Therapeutics from $56.00 to $76.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Finally, Raymond James Financial restated a "strong-buy" rating and set a $84.00 target price on shares of Vera Therapeutics in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $81.15.
View Our Latest Research Report on Vera Therapeutics
About Vera Therapeutics
(
Get Free Report)
Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.
Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
